(GMAB) Genmab AS - Performance -16.9% in 12m
GMAB performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-58.91%
#85 in Peer-Group
Rel. Strength
25.51%
#5524 in Stock-Universe
Total Return 12m
-16.86%
#77 in Peer-Group
Total Return 5y
-38.22%
#48 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | 12.2 |
| P/E Forward | 11.4 |
| High / Low | USD |
|---|---|
| 52 Week High | 28.48 USD |
| 52 Week Low | 17.98 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 37.83 |
| Buy/Sell Signal +-5 | 1.65 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: GMAB (-16.9%) vs XBI (-10.8%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
2.52% | 66.7% | 77.4% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-11.7% | -9.92% | 139% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
-3.21% | -7.33% | 26.4% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
-0.28% | 31.9% | -4.56% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
0.91% | -10.3% | 0.26% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.3% | 65.1% | -9.72% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| PTCT NASDAQ PTC Therapeutics |
0.02% | 56.7% | -7.85% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
2.86% | 34.5% | 14.3% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: GMAB vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for GMAB
| Total Return (including Dividends) | GMAB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -5.10% | 2.09% | 4.55% |
| 3 Months | 5.52% | 2.27% | 10.78% |
| 12 Months | -16.86% | -10.84% | 14.71% |
| 5 Years | -38.22% | -26.24% | 112.53% |
| Trend Score (consistency of price movement) | GMAB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -51.3% | 18.8% | 79.2% |
| 3 Months | 72.6% | 71.5% | 92.9% |
| 12 Months | -74.4% | -84.3% | 44.2% |
| 5 Years | -68.8% | -52.7% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th42.00 | -7.04% | -9.23% |
| 3 Month | %th53.50 | 3.18% | -4.75% |
| 12 Month | %th62.00 | -6.76% | -27.52% |
| 5 Years | %th78.00 | -16.23% | -70.93% |
FAQs
Does Genmab AS (GMAB) outperform the market?
No,
over the last 12 months GMAB made -16.86%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.84%.
Over the last 3 months GMAB made 5.52%, while XBI made 2.27%.
Performance Comparison GMAB vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
GMAB vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.1% | -9.7% | -7.1% | -32% |
| US NASDAQ 100 | QQQ | -3.9% | -10.7% | -9.2% | -32% |
| German DAX 40 | DAX | -2.9% | -5.1% | -20% | -47% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -2.7% | -9.3% | -5.1% | -34% |
| Hongkong Hang Seng | HSI | -2.6% | -10.9% | -22.8% | -52% |
| India NIFTY 50 | INDA | -2.6% | -7.2% | -6.8% | -17% |
| Brasil Bovespa | EWZ | -4.4% | -12.9% | -31.6% | -30% |
GMAB vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -4.6% | -11.9% | -13.7% | -46% |
| Consumer Discretionary | XLY | -1.5% | -6.7% | 1.7% | -37% |
| Consumer Staples | XLP | 0.4% | -3.5% | -5.3% | -26% |
| Energy | XLE | 1.3% | -8.6% | -1.6% | -13% |
| Financial | XLF | -3.2% | -8.2% | -10.1% | -46% |
| Health Care | XLV | -2.1% | -7.1% | 0.2% | -11% |
| Industrial | XLI | -2.6% | -8.8% | -13.7% | -41% |
| Materials | XLB | -1.1% | -6.7% | -6.4% | -20% |
| Real Estate | XLRE | 1.4% | -5.1% | -4.4% | -29% |
| Technology | XLK | -4.4% | -14% | -10.3% | -29% |
| Utilities | XLU | -0.6% | -5.2% | -10.4% | -41% |
| Aerospace & Defense | XAR | -5% | -15% | -28.5% | -70% |
| Biotech | XBI | -0.9% | -7.2% | 6.9% | -6% |
| Homebuilder | XHB | -1.3% | -11.2% | 4.2% | -18% |
| Retail | XRT | 0% | -6.5% | 1.7% | -23% |
GMAB vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 4.2% | -10.2% | 2.22% | -7% |
| Natural Gas | UNG | 9.2% | 4.3% | 8.1% | -9% |
| Gold | GLD | 1.9% | -2.9% | -26.9% | -58% |
| Silver | SLV | 0.4% | -9% | -25.6% | -39% |
| Copper | CPER | -3.3% | -9.3% | -26.8% | -32% |
GMAB vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -1.8% | -8.7% | -3.9% | -19% |
| iShares High Yield Corp. Bond | HYG | -1% | -7% | -6% | -28% |